GASTROESOPHAGEAL-JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL-JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL-JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL-JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests drug combo to keep stomach cancer at bay
Disease control CompletedThis large, completed study tested if adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal cancer. The goal was to see if the combination, given both before and after surgery, helps keep the cancer from returning and i…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for stomach cancer: drug combo tested in major trial
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. It involved 120 Chinese adults who hadn't received prior treatment, giving the drug combination both before and after surg…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Real-World cancer treatment data revealed
Knowledge-focused CompletedThis study looked back at medical records to understand how well the drug nivolumab worked in real-world practice for 260 patients in China with advanced stomach cancer. It did not test a new treatment but collected information on how long the cancer was controlled and how patien…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC